Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2018 Filed Apr 18, 2018 01:59 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000919574-18-003087 · p7869143.xml · nonDerivative · entry 9 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,712,500 F3 · ownership.nature: The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 01:59 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000919574-18-003087 · p7869143.xml · nonDerivative · entry 8 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,712,500 F3 · ownership.nature: The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 01:59 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
PurchaseCommon Stock | 1,895,610 | $0.44 | $837,670.06 |
DisclosureSEC source: 0000919574-18-003087 · p7869143.xml · nonDerivative · entry 7 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,712,500 F5 · price: This constitutes the weighted average purchase price. The prices range from $0.393 to $0.492. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · ownership.direct: The reported securities are directly owned by Armistice Capital Master Fund, Ltd. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 21:24 UTC |
Garanzini MichaelChief Commercial Officer
|
PurchaseWarrants (right to buy) · Derivative | 156,250 | Not disclosed Strike: $0.32 | Not disclosed |
DisclosureSEC source: 0001144204-18-021207 · tv491364_4.xml · derivative · entry 2 Garanzini Michael · CIK 0001722844 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,250 Underlying: Common Stock · 156,250 shares Expires 2023-04-17 F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $0.32 per share of common stock and warrant in connection with the Issuer's public offering that closed on April 17, 2018. Each warrant will be exercisable during the period commencing on April 17, 2018 and ending on April 17, 2023 at an exercise price of $0.32. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 21:24 UTC |
Garanzini MichaelChief Commercial Officer
|
PurchaseCommon Stock | 156,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-021207 · tv491364_4.xml · nonDerivative · entry 1 Garanzini Michael · CIK 0001722844 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,250 F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $0.32 per share of common stock and warrant in connection with the Issuer's public offering that closed on April 17, 2018. Each warrant will be exercisable during the period commencing on April 17, 2018 and ending on April 17, 2023 at an exercise price of $0.32. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 21:23 UTC |
FROM STEPHENDirector · President and CEO
|
PurchaseWarrants (right to buy) · Derivative | 125,000 | Not disclosed Strike: $0.32 | Not disclosed |
DisclosureSEC source: 0001144204-18-021206 · tv491363_4.xml · derivative · entry 2 FROM STEPHEN · CIK 0001620137 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2023-04-17 F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $0.32 per share of common stock and warrant in connection with the Issuer's public offering that closed on April 17, 2018. Each warrant will be exercisable during the period commencing on April 17, 2018 and ending on April 17, 2023 at an exercise price of $0.32. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 21:23 UTC |
FROM STEPHENDirector · President and CEO
|
PurchaseCommon Stock | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-021206 · tv491363_4.xml · nonDerivative · entry 1 FROM STEPHEN · CIK 0001620137 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,820 F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $0.32 per share of common stock and warrant in connection with the Issuer's public offering that closed on April 17, 2018. Each warrant will be exercisable during the period commencing on April 17, 2018 and ending on April 17, 2023 at an exercise price of $0.32. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 21:22 UTC |
Romano SarahChief Financial Officer
|
PurchaseWarrants (right to buy) · Derivative | 62,500 | Not disclosed Strike: $0.32 | Not disclosed |
DisclosureSEC source: 0001144204-18-021205 · tv491362_4.xml · derivative · entry 2 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2023-04-17 F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $0.32 per share of common stock and warrant in connection with the Issuer's public offering that closed on April 17, 2018. Each warrant will be exercisable during the period commencing on April 17, 2018 and ending on April 17, 2023 at an exercise price of $0.32. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 21:22 UTC |
Romano SarahChief Financial Officer
|
PurchaseCommon Stock | 62,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-021205 · tv491362_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,863 F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $0.32 per share of common stock and warrant in connection with the Issuer's public offering that closed on April 17, 2018. Each warrant will be exercisable during the period commencing on April 17, 2018 and ending on April 17, 2023 at an exercise price of $0.32. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 01:59 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
PurchaseWarrants · Derivative | 0 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0000919574-18-003087 · p7869143.xml · derivative · entry 12 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,468,750 Underlying: Common Stock · 0 shares Expires 2023-04-17 F6 · derivative.exercise_date: These warrants are currently exercisable, subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd.from exercising the warrants if it would be more than a 9.99% beneficial owner of the Common Shares following such exercise. F3 · ownership.nature: The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 01:59 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
PurchaseWarrants · Derivative | 0 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0000919574-18-003087 · p7869143.xml · derivative · entry 11 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,468,750 Underlying: Common Stock · 0 shares Expires 2023-04-17 F6 · derivative.exercise_date: These warrants are currently exercisable, subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd.from exercising the warrants if it would be more than a 9.99% beneficial owner of the Common Shares following such exercise. F3 · ownership.nature: The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 01:59 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
PurchaseWarrants · Derivative | 5,468,750 | $0.21 Strike: $0.32 | $1,121,093.75 |
DisclosureSEC source: 0000919574-18-003087 · p7869143.xml · derivative · entry 10 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,468,750 Underlying: Common Stock · 5,468,750 shares Expires 2023-04-17 F6 · derivative.exercise_date: These warrants are currently exercisable, subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd.from exercising the warrants if it would be more than a 9.99% beneficial owner of the Common Shares following such exercise. F2 · ownership.direct: The reported securities are directly owned by Armistice Capital Master Fund, Ltd. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 01:59 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000919574-18-003087 · p7869143.xml · nonDerivative · entry 6 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,816,890 F3 · ownership.nature: The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 01:59 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000919574-18-003087 · p7869143.xml · nonDerivative · entry 5 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,816,890 F3 · ownership.nature: The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 01:59 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
PurchaseCommon Stock | 1,159,167 | $0.38 | $435,730.88 |
DisclosureSEC source: 0000919574-18-003087 · p7869143.xml · nonDerivative · entry 4 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,816,890 F4 · price: This constitutes the weighted average purchase price. The prices range from $0.329 to $0.395. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · ownership.direct: The reported securities are directly owned by Armistice Capital Master Fund, Ltd. Read SEC document |
| April 13, 2018 Filed Apr 18, 2018 01:59 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000919574-18-003087 · p7869143.xml · nonDerivative · entry 3 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,657,723 F3 · ownership.nature: The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd. Read SEC document |
| April 13, 2018 Filed Apr 18, 2018 01:59 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000919574-18-003087 · p7869143.xml · nonDerivative · entry 2 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,657,723 F3 · ownership.nature: The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd. Read SEC document |
| April 13, 2018 Filed Apr 18, 2018 01:59 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
PurchaseCommon Stock | 7,425,193 | $0.33 | $2,466,649.11 |
DisclosureSEC source: 0000919574-18-003087 · p7869143.xml · nonDerivative · entry 1 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,657,723 F1 · price: This constitutes the weighted average purchase price. The prices range from $0.30 to $0.351. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · ownership.direct: The reported securities are directly owned by Armistice Capital Master Fund, Ltd. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 16:13 UTC |
Wirostko BarbaraChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001144204-18-012235 · tv487518_4.xml · derivative · entry 1 Wirostko Barbara · CIK 0001669087 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-28 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 28, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 16:18 UTC |
Mann BrendaVP of Research & Development
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001144204-18-012243 · tv487520_4.xml · derivative · entry 1 Mann Brenda · CIK 0001668858 · VP of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-02-28 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 28, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:15 UTC |
MANZO MICHAEL P.Vice President of Engineering
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001144204-18-012236 · tv487519_4.xml · derivative · entry 1 MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-28 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 28, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:21 UTC |
Romano SarahChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001144204-18-012247 · tv487523_4.xml · derivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-28 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 28, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:11 UTC |
FROM STEPHENDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001144204-18-012234 · tv487514_4.xml · derivative · entry 1 FROM STEPHEN · CIK 0001620137 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-02-28 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 28, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 16:07 UTC |
Wirostko BarbaraChief Medical Officer
|
OtherCommon Stock | 12,355 | $1.01 | $12,478.55 |
DisclosureSEC source: 0001144204-18-000497 · tv482538_4.xml · nonDerivative · entry 1 Wirostko Barbara · CIK 0001669087 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,397 F1 · kind: The shares were acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2017 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 16:07 UTC |
Mann BrendaVP of Research & Development
|
OtherCommon Stock | 6,722 | $1.01 | $6,789.22 |
DisclosureSEC source: 0001144204-18-000495 · tv482537_4.xml · nonDerivative · entry 1 Mann Brenda · CIK 0001668858 · VP of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,473 F1 · kind: The shares were acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2017 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:10 UTC |
Romano SarahChief Financial Officer
|
OtherCommon Stock | 11,863 | $1.01 | $11,981.63 |
DisclosureSEC source: 0001144204-18-000500 · tv482539_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,363 F1 · kind: The shares were acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2017 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:05 UTC |
FROM STEPHENDirector · President and CEO
|
OtherCommon Stock | 12,355 | $1.01 | $12,478.55 |
DisclosureSEC source: 0001144204-18-000492 · tv482535_4.xml · nonDerivative · entry 1 FROM STEPHEN · CIK 0001620137 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,820 F1 · kind: The shares were acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2017 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 23:53 UTC |
Garanzini MichaelChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001144204-17-060013 · tv479901_4.xml · derivative · entry 1 Garanzini Michael · CIK 0001722844 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2027-11-17 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on November 1, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| November 17, 2017 Filed Nov 22, 2017 21:15 UTC |
Garanzini MichaelChief Commercial Officer
|
GrantCommon Stock | 15,000 | $1.07 | $16,050.00 |
DisclosureSEC source: 0001144204-17-060667 · tv480167_4.xml · nonDerivative · entry 1 Garanzini Michael · CIK 0001722844 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.06 to $1.088, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| September 15, 2017 Filed Sep 15, 2017 16:29 UTC |
Wirostko BarbaraChief Medical Officer
|
GrantCommon Stock | 9,000 | $1.20 | $10,800.00 |
DisclosureSEC source: 0001144204-17-048266 · v475305_4.xml · nonDerivative · entry 3 Wirostko Barbara · CIK 0001669087 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,042 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.19 to $1.21, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 16:29 UTC |
Wirostko BarbaraChief Medical Officer
|
GrantCommon Stock | 9,000 | $1.23 | $11,070.00 |
DisclosureSEC source: 0001144204-17-048266 · v475305_4.xml · nonDerivative · entry 2 Wirostko Barbara · CIK 0001669087 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By husband Disclosed balance after: 50,700 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.24, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 16:29 UTC |
Wirostko BarbaraChief Medical Officer
|
GrantCommon Stock | 1,200 | $1.22 | $1,464.00 |
DisclosureSEC source: 0001144204-17-048266 · v475305_4.xml · nonDerivative · entry 1 Wirostko Barbara · CIK 0001669087 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,042 Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 20:05 UTC |
Romano SarahInterim CFO
|
PurchaseCommon Stock | 10,000 | $1.00 | $10,000.00 |
DisclosureSEC source: 0001144204-17-043873 · v473586_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Read SEC document |
| August 10, 2017 Filed Aug 10, 2017 21:57 UTC |
FROM STEPHENDirector · President and CEO
|
PurchaseCommon Stock | 12,500 | $1.03 | $12,875.00 |
DisclosureSEC source: 0001144204-17-042118 · v473009_4.xml · nonDerivative · entry 1 FROM STEPHEN · CIK 0001620137 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,465 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9901 to $1.03, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 16:24 UTC |
Wirostko BarbaraChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033632 · v469456_4.xml · derivative · entry 1 Wirostko Barbara · CIK 0001669087 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on June 21, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 16:25 UTC |
Mann BrendaVP of Research & Development
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033638 · v469457_4.xml · derivative · entry 1 Mann Brenda · CIK 0001668858 · VP of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on June 21, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 16:18 UTC |
TYLE PRAVEENDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033622 · v469452_4.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on June 21, 2018. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 16:18 UTC |
CHANEY PAUL GDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033620 · v469451_4.xml · derivative · entry 1 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on June 21, 2018. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 20:28 UTC |
MANZO MICHAEL P.Vice President of Engineering
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033644 · v469460_4.xml · derivative · entry 1 MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on June 21, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 20:26 UTC |
Romano SarahInterim CFO
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033640 · v469459_4.xml · derivative · entry 1 Romano Sarah · CIK 0001697536 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on June 21, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 20:22 UTC |
FROM STEPHENDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033630 · v469455_4.xml · derivative · entry 1 FROM STEPHEN · CIK 0001620137 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on June 21, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 20:20 UTC |
HANCOCK THOMASDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033625 · v469454_4.xml · derivative · entry 1 HANCOCK THOMAS · CIK 0001619727 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on June 21, 2018. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 20:19 UTC |
BALLAND THOMASDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033623 · v469453_4.xml · derivative · entry 1 BALLAND THOMAS · CIK 0001620377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on June 21, 2018. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 20:17 UTC |
GOLDBERG MORTONDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033618 · v469450_4.xml · derivative · entry 1 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on June 21, 2018. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 20:16 UTC |
MALFROY-CAMINE BERNARDDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033617 · v469449_4.xml · derivative · entry 1 MALFROY-CAMINE BERNARD · CIK 0001619732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on June 21, 2018. Read SEC document |
| June 14, 2017 Filed Jun 14, 2017 20:51 UTC |
Romano SarahInterim CFO
|
PurchaseWarrants (right to buy) · Derivative | 20,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001144204-17-032554 · v469022_form4.xml · derivative · entry 2 Romano Sarah · CIK 0001697536 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2022-06-14 F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $1.50 per share of common stock and warrant in connection with the Issuer's public offering that closed on June 14, 2017. Each warrant will be exercisable during the period commencing on June 14, 2017 and ending on June 14, 2022 at an exercise price of $1.50. Read SEC document |
| June 14, 2017 Filed Jun 14, 2017 20:51 UTC |
Romano SarahInterim CFO
|
PurchaseCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-032554 · v469022_form4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $1.50 per share of common stock and warrant in connection with the Issuer's public offering that closed on June 14, 2017. Each warrant will be exercisable during the period commencing on June 14, 2017 and ending on June 14, 2022 at an exercise price of $1.50. Read SEC document |
| June 14, 2017 Filed Jun 14, 2017 20:50 UTC |
FROM STEPHENDirector · President and CEO
|
PurchaseWarrants (right to buy) · Derivative | 60,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001144204-17-032552 · v469021_form4.xml · derivative · entry 2 FROM STEPHEN · CIK 0001620137 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2022-06-14 F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $1.50 per share of common stock and warrant in connection with the Issuer's public offering that closed on June 14, 2017. Each warrant will be exercisable during the period commencing on June 14, 2017 and ending on June 14, 2022 at an exercise price of $1.50. Read SEC document |
| June 14, 2017 Filed Jun 14, 2017 20:50 UTC |
FROM STEPHENDirector · President and CEO
|
PurchaseCommon Stock | 60,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-032552 · v469021_form4.xml · nonDerivative · entry 1 FROM STEPHEN · CIK 0001620137 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,965 F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $1.50 per share of common stock and warrant in connection with the Issuer's public offering that closed on June 14, 2017. Each warrant will be exercisable during the period commencing on June 14, 2017 and ending on June 14, 2022 at an exercise price of $1.50. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 19:41 UTC |
CHANEY PAUL GDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 17,570 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001144204-17-031102 · v468441_4.xml · derivative · entry 2 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,570 shares Expires 2017-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The reporting person was granted an option to purchase these shares pursuant to the Issuer's 2005 Equity Incentive Plan. The option became exercisable immediately at the time of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.